Cosette Pharmaceuticals announced it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company’s executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio.
In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible for driving performance across Cosette’s marketed portfolio of 21 brands, supporting the integration and growth of acquired assets, and ensuring strong alignment between commercial execution and the company’s broader strategic and financial objectives.
“David’s appointment reflects Cosette’s continued investment in the commercial capabilities required to support the next level of growth,” said Apurva Saraf, President and CEO of Cosette Pharmaceuticals. “His deep expertise in commercial strategy, market access, portfolio management, and P&L leadership will be valuable as we continue to strengthen our branded portfolio and integrate new assets.”
David brings more than 25 years of commercial and enterprise leadership experience across oncology, rare disease and gene therapy in specialty pharmaceuticals markets. Most recently, David served as Vice President, Business Unit Head, US Oncology at Ferring Pharmaceuticals, where he held full U.S. P&L ownership responsibility. He also previously served as Franchise General Manager at Melinta Therapeutics and spent 17 years at Merck & Co./Schering-Plough in progressive global, U.S., and regional commercial leadership roles.
“I am proud to join Cosette, an organization that has built a differentiated platform with brands that help patients live better lives,” David shared. “I am excited to join a leadership team that will take Cosette’s branded portfolio to the next phase of corporate growth by maximizing current and acquired assets, expanding patient access to important medicines, and alleviating the burden and suffering of patients and their families.”
David earned his Master of Business Administration and Bachelor of Science in Finance from Seton Hall University’s W. Paul Stillman School of Business. He also served as a board member of Enhanced HealthCare Solutions.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!